...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The British Journal of Nutrition >Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial.
【24h】

Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial.

机译：在一项随机对照试验中，发酵乳中的加氏乳杆菌SBT2055对成年人腹部肥胖的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Consumption of fermented milk (FM) containing a probiotic, Lactobacillus gasseri SBT2055 (LG2055), previously showed a reduction in abdominal adiposity in a randomised controlled trial (RCT) using FM with 108 colony-forming units (cfu) of LG2055/g. However, whether the effectiveness is observed at lower concentrations, the recommended minimum or intermediate levels of probiotics (106 or 107 cfu/g, respectively), remains to be examined. A multi-centre, double-blind, parallel-group RCT was conducted using 210 healthy Japanese adults with large visceral fat areas (80.2-187.8 cm2). They were balanced for their baseline characteristics and randomly assigned to three groups receiving FM containing 107, 106 or 0 (control) cfu LG2055/g of FM, and were asked to consume 200 g FM/d for 12 weeks. Abdominal visceral fat areas, which were determined by computed tomography, at week 12, changed from baseline by an average of -8.5% (95% CI -11.9, -5.1; P<0.01) in the 107 dose group, and by -8.2% (95% CI -10.8, -5.7; P<0.01) in the 106 dose group. Other measures including BMI, waist and hip circumferences, and body fat mass were also significantly decreased from baseline at week 12 in both groups; interestingly, the cessation of taking FM for 4 weeks attenuated these effects. In the control group, none of these parameters significantly decreased from baseline. These findings demonstrate that consumption of LG2055 at doses as low as the order of 108 cfu/d exhibited a significant lowering effect on abdominal adiposity, and suggest that constant consumption might be needed to maintain the effect.
机译：食用含有益生菌加氏乳杆菌SBT2055（LG2055）的发酵乳（FM）之前，在使用10 8 集落形成单位的FM的随机对照试验（RCT）中，腹部脂肪减少了（ cfu）LG2055 / g。但是，是否在较低浓度下观察到效果，建议的最低或中等水平的益生菌（分别为10 6 或10 7 cfu / g）仍有待研究。 。对210名健康的日本内脏脂肪区域大（80.2-187.8 cm 2 ）的成年人进行了多中心，双盲，平行组RCT。他们平衡了基线特征，并随机分为三组，分别接受含有10 7 ，10 6 或0（对照）cfu LG2055 / g FM的FM，并询问连续12周消耗200克FM / d。在10 7 剂量组，在10 6 剂量组中下降-8.2％（95％CI -10.8，-5.7; P <0.01）。两组的第12周的其他指标（包括BMI，腰围和臀围以及身体脂肪量）也均较基线水平显着降低。有趣的是，停止服用FM 4周减弱了这些影响。在对照组中，这些参数均未从基线显着降低。这些发现表明，低至10 8 cfu / d剂量的LG2055摄入量对腹部肥胖具有明显的降低作用，并暗示可能需要持续消耗以保持这种作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号